Taiwan Liposome Company Current Assets

Taiwan Liposome Company's current assets stands at $990M as of June 2021. That compares with $1.4B in the prior-year period — down 29.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Taiwan Liposome Company reported $990M in current assets versus $1.4B a year earlier — a 29.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.4B in the prior-year period — down 29.8% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Taiwan Liposome Company's current assets evolved across reporting periods, while the comparison chart places TLC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Taiwan Liposome Company's reading of $990M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.